cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.25449355.v1
title: <b>Integrated Analysis of Tumor-Associated Macrophages and M2 Macrophages in CRC: Unraveling Molecular Heterogeneity and Developing a Novel Risk Signature</b>

description: Background: Emerging investigations have increasingly highlighted the critical role of tumor-associated macrophages (TAMs) and M2 macrophages in cancer development, progression, and metastasis, marking them as potential targets in various cancer types. The main objective of this research is to discover new biomarkers associated with TAM-M2 macrophages in colorectal cancer (CRC) and to dissect the molecular heterogeneity of CRC by combining single-cell RNA sequencing and bulk RNA-seq data.Methods: By utilizing weighted gene co-expression network analysis (WGCNA), we acquired TAM-M2-associated genes by intersecting TAM marker genes obtained from scRNA-seq data with module genes of M2 macrophages derived from bulk RNA-seq data. We employed least absolute shrinkage and selection operator (LASSO) Cox analysis to select predictive biomarkers from these TAM-M2-related genes. Quantitative polymerase chain reaction (qPCR) was employed to validate the mRNA expression levels of the genes identified in the screening. This led to the development of the TAM-M2-related signature (TAMM2RS). We also conducted functional and immune landscape analyses of different risk groups.Results: The combination of scRNA-seq and bulk RNA-seq analyses yielded 377 TAM-M2-related genes. DAPK1, NAGK, and TRAF1 emerged as key prognostic genes in CRC, which were identified through LASSO Cox analysis. Utilizing these genes, we constructed and validated the TAMM2RS, demonstrating its effectiveness in predicting survival in CRC patients.Conclusion: Our research offers a thorough investigation into the molecular mechanisms associated with TAM-M2 macrophages in CRC and unveils potential therapeutic targets, offering new insights for treatment strategies in colorectal cancer.<br>
DOI: 10.5281/zenodo.10848850
title: 日琉方言の準体形式:調査票とデータ集

description: 日琉方言の準体形式:調査票とデータ集

作成者:小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建

このデータセットは、日琉方言の準体形式の記述・対照のための調査票と、その調査票を用いた調査結果である。

調査票のほか、次の方言の調査結果データを含む(†は音声データ付)。詳細は readme_nmnl_data.pdf 参照。

福島県会津方言(報告者:福田建)山梨県奈良田方言(報告者:小西いずみ)†富山市方言(報告者:小西いずみ)福井県越前市方言(報告者:西川由佳)摂津方言1(報告者:岩﨑凜太郎)摂津方言2(報告者:陳 港)†広島市方言(報告者:河本健汰)長崎県佐世保方言(報告者:平井偉在耶)熊本市方言(報告者:阪上健夫)

また、調査票の解説にあたる次の記事を含む。小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建(2024)「日琉方言の準体形式調査票」『日本語学論集』第20号, pp.86(149)-104(131)
DOI: 10.5281/zenodo.10848851
title: 日琉方言の準体形式:調査票とデータ集

description: 日琉方言の準体形式:調査票とデータ集

作成者:小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建

このデータセットは、日琉方言の準体形式の記述・対照のための調査票と、その調査票を用いた調査結果である。

調査票のほか、次の方言の調査結果データを含む(†は音声データ付)。詳細は readme_nmnl_data.pdf 参照。

福島県会津方言(報告者:福田建)山梨県奈良田方言(報告者:小西いずみ)†富山市方言(報告者:小西いずみ)福井県越前市方言(報告者:西川由佳)摂津方言1(報告者:岩﨑凜太郎)摂津方言2(報告者:陳 港)†広島市方言(報告者:河本健汰)長崎県佐世保方言(報告者:平井偉在耶)熊本市方言(報告者:阪上健夫)

また、調査票の解説にあたる次の記事を含む。小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建(2023)「日琉方言の準体形式調査票」『日本語学論集』第20号, pp.86(149)-104(131)
DOI: 10.5281/zenodo.10849165
title: 日琉方言の準体形式:調査票とデータ集

description: 日琉方言の準体形式:調査票とデータ集

作成者:小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建

このデータセットは、日琉方言の準体形式の記述・対照のための調査票と、その調査票を用いた調査結果である。

調査票のほか、次の方言の調査結果データを含む(†は音声データ付)。詳細は readme_nmnl_data.pdf 参照。

福島県会津方言(報告者:福田建)山梨県奈良田方言(報告者:小西いずみ)†富山市方言(報告者:小西いずみ)福井県越前市方言(報告者:西川由佳)摂津方言1(報告者:岩﨑凜太郎)摂津方言2(報告者:陳 港)†広島市方言(報告者:河本健汰)長崎県佐世保方言(報告者:平井偉在耶)熊本市方言(報告者:阪上健夫)

また、調査票の解説にあたる次の記事を含む。小西 いずみ・阪上 健夫・岩﨑 凜太郎・河本 健汰・陳 港・西川 由佳・朴 校演・平井 偉在耶・福田 建(2024)「日琉方言の準体形式調査票」『日本語学論集』第20号, pp.86(149)-104(131)
DOI: 10.48597/zy5j-yfsd
title: Measurement of Mercury at Råö

description: Measurement of Mercury at Råö
DOI: 10.5281/zenodo.10356234
title: On the Landau gauge ghost-gluon-vertex close to and in the conformal window - data release

description: On the Landau gauge ghost-gluon-vertex close to and in the conformal window
This repository contains the data presented in "On the Landau gauge ghost-gluon-vertex close to and in the conformal window". See the file README.md for more information.
DOI: 10.5281/zenodo.10356235
title: On the Landau gauge ghost-gluon-vertex close to and in the conformal window - data release

description: On the Landau gauge ghost-gluon-vertex close to and in the conformal window
This repository contains the data presented in "On the Landau gauge ghost-gluon-vertex close to and in the conformal window". See the file README.md for more information.
DOI: 10.5281/zenodo.10849201
title: On the Landau gauge ghost-gluon-vertex close to and in the conformal window - data release

description: On the Landau gauge ghost-gluon-vertex close to and in the conformal window
This repository contains the data presented in "On the Landau gauge ghost-gluon-vertex close to and in the conformal window". See the file README.md for more information.
DOI: 10.34808/fzps-pw04
title: NADES propolis extracts - update 2023 and synthesis of derivatives of propolis ingredients

description: This dataset contains results of our investigation aiming in determination of antimicrobial potential of the propolis extracts produced with deep eutectic solvents
1. kill time assay
2. synthesis of derivatives of propolis components - e.g. NMR data
3. COSMO RS analysis
DOI: 10.48597/tjg3-hh3v
title: Measurement of Mercury at Råö

description: Measurement of Mercury at Råö
DOI: 10.48597/29j2-zvpc
title: Measurement of Mercury at Råö

description: Measurement of Mercury at Råö
DOI: 10.57780/sm1-4f787c3
title: SMOS-CryoSat L4 Sea Ice Thickness

description: SMOS-CryoSat L4 Sea Ice Thickness
DOI: 10.6084/m9.figshare.25451581
title: Untitled Item

description: Frugality project
DOI: 10.6084/m9.figshare.25451581.v1
title: Untitled Item

description: Frugality project
DOI: 10.48786/edbt.2024.30
title: Analysis of Open Government Datasets From a Data Design and Integration Perspective
DOI: 10.48786/edbt.2024.14
title: Fair Spatial Indexing: A paradigm for Group Spatial Fairness
DOI: 10.48786/edbt.2024.15
title: Querying For Actions Over Videos
DOI: 10.48786/edbt.2024.31
title: The Missing Link? On the In-Between Instance Detection Task
DOI: 10.48786/edbt.2024.16
title: Interactive Graph Repairs for Neighborhood Constraints
DOI: 10.48786/edbt.2024.18
title: CSR+: A Scalable Efficient CoSimRank Search Algorithm with Multi-Source Queries on Massive Graphs
DOI: 10.48786/edbt.2024.19
title: FALCC: Efficiently performing locally fair and accurate classifications
DOI: 10.48786/edbt.2024.32
title: Querying Large Language Models with SQL
DOI: 10.48786/edbt.2024.20
title: Relational Data Imputation with Graph Neural Networks
DOI: 10.48786/edbt.2024.21
title: Seraph: Continuous Queries on Property Graph Streams
DOI: 10.48786/edbt.2024.22
title: GSim+: Efficient Retrieval of Node-to-Node Similarity Across Two Graphs at Billion Scale
DOI: 10.48786/edbt.2024.23
title: MCF-KV: Multi-Cuckoo-Filter Index based Key-Value Store with Persistent Memory
DOI: 10.48786/edbt.2024.24
title: Efficient Semantic Similarity Search over Spatio-textual Data
DOI: 10.48786/edbt.2024.25
title: EMBA: Entity Matching using Multi-Task Learning of BERT with Attention-over-Attention
DOI: 10.48786/edbt.2024.26
title: (Privately) Estimating Linkage Quality for Record Linkage
DOI: 10.48786/edbt.2024.27
title: QPSeeker: An Efficient Neural Planner combining both data and queries through Variational Inference
DOI: 10.48786/edbt.2024.28
title: Size-bounded Community Search over Large Bipartite Graphs
DOI: 10.48786/edbt.2024.29
title: Optimizing Goodput through Sharing for Batch Analytics with Deadlines
DOI: 10.6084/m9.figshare.25451437
title: The genome information files of Stellera chamaejasme

description: AbstractUnderstanding how populations diverge and new species arise is a central questionin evolutionary biology. “Allopatric” divergence through geographical isolation is con?sidered to be the commonest mechanism generating species biodiversity in mountainecosystems. However, the underlying genomic dynamics, especially genomic islandsof elevated divergence and genes that are highly diverged as a result of lineage?specific selection, remain poorly understood. <i>Stellera chamaejasme</i> has a wide geo?graphical range across the Qinghai–Tibet Plateau and northern China, making it agood model with which to explore genomic divergence during speciation in mountainecosystems. We assembled a high-quality, chromosome-level genome for this speciesand resequenced the genomes of 24 populations across its major distribution. Ourpopulation genomic analyses recovered four distinct genetic lineages correspond?ing to geographical distributions with contrasting environments. However, we re?vealed continuous gene flow during the historical divergences of these four lineages.Interlineage hybrids and plastome introgressions were frequently found in regions ofcontact, which further increased gene flow between two contacting lineages in therecent past. The elevated divergences were highly heterogeneous across the genomeand selection of ancestral polymorphisims and divergence hitchhiking contributedgreatly to the formation of genomic islands. The highly diverged and lineage-specificpositively selected genes within and outside genomic islands were annotated to bemainly involved in local adaptation. Our results suggest that genomic divergence in<i>S. chamaejasme</i> is likely to have been triggered and maintained by local selection to?gether with geographical isolation.
DOI: 10.5281/zenodo.10828394
title: Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer

description: This repository includes source data used to genrtate all tables and figures  for published stduy "Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer". Besides, a small set of digital images for different class of cervical smear samples are included.
DOI: 10.5281/zenodo.10828395
title: Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer

description: This repository includes source data used to genrtate all tables and figures  for published stduy "Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer". Besides, a small set of digital images for different class of cervical smear samples are included.
DOI: 10.48597/8mgw-4hfy
title: Measurement of Pm10_mass at Råö

description: Measurement of Pm10_mass at Råö
DOI: 10.48597/xfqn-979n
title: Measurement of Pm25_mass at Råö

description: Measurement of Pm25_mass at Råö
DOI: 10.7910/dvn/9uf1zm/4cpaul
title: epi indicators-all years-1.tab

description: A Stata dta file of the EPI component scores for every year.
DOI: 10.7910/dvn/9uf1zm/5ptw1t
title: README.md

description: Readme for the data
DOI: 10.7910/dvn/9uf1zm/oxorpr
title: state indicators 2018-1.tab

description: The 2018 EPI component scores in Stata dta format.
DOI: 10.7910/dvn/9uf1zm/cb0ygz
title: 2016-epi-methodology.pdf

description: Full methodology document for the EPI
DOI: 10.7910/dvn/9uf1zm/efvnjk
title: 2018-epi-update.pdf

description: The updates and changes to how the 2018 scores were calculated and updates in relevant measures.
DOI: 10.7910/dvn/9uf1zm/mry2q6
title: epi indicators-all years.tab

description: A csv of the EPI component scores for every year.
DOI: 10.7910/dvn/9uf1zm/ztc8tn
title: state indicators 2018.tab

description: The 2018 EPI component scores in csv format.
DOI: 10.57780/sm1-294cb1b
title: SMOS L2 OS V700

description: SMOS L2 OS version 700
DOI: 10.6084/m9.figshare.25451566
title: PM10 data

description: This is PM10 data for sites worldwide.
DOI: 10.6084/m9.figshare.22352863.v1
title: The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the Netherlands

description: Type-2 Diabetes Mellitus (T2DM) increases both the patient risk of cardiovascular disease (CVD) and renal outcomes, such as chronic kidney disease (CKD). Recent clinical trials of the glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is) have shown benefits in preventing CVD events and progression of CKD, leading to an update of the Dutch T2DM treatment guideline for patients at risk. The aim of this study is to assess the health and economic impact of the guideline-recommended utilisation of SGLT2is in the Netherlands. The patient population at risk was determined by multiplying Dutch T2DM prevalence rates with the total numbers of inhabitants of the Netherlands in 2020. Subsequently, two analyses, comparing a treatment setting before and after implementation of the new guideline for SGLT2is, were conducted. Clinical and adverse event rates in both settings as well as direct healthcare costs were sourced from the literature. Total costs were calculated by multiplying disease prevalence, event rates and costs associated to outcomes. One-time disutilities per event were included to estimate the health impact. The potential health and economic impact of implementing the updated guideline was calculated. Using a 5-year time horizon, the guideline-suggested utilisation of SGLT2is resulted in a health impact equal to 4,835 quality adjusted life years gained (0.0031 per patient per year) and €461 million cost-savings. The costs of treatment with SGLT2is were €813 million. Hence the net budget impact was €352 million for the total Dutch T2DM population, which translated to €0,57 per patient per day. SGLT2is offer an option to reduce the number of CVD and CKD related events and associated healthcare costs and health losses in the Netherlands. Further research is needed to include the benefits of improved T2DM management options from a broader societal perspective.
DOI: 10.6084/m9.figshare.22332160
title: Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States

description: No research to date has examined antipsychotic (AP) use, healthcare resource use (HRU), costs, and quality of care among those with schizophrenia in the Medicare program despite it serving as the primary payer for half of individuals with schizophrenia in the US. To provide national estimates and assess regional variation in AP treatment utilization, HRU, costs, and quality measures among Medicare beneficiaries with schizophrenia. Cross-sectional descriptive analysis of 100% Medicare claims data from 2019. The sample included all adult Medicare beneficiaries with continuous fee-for-service coverage and ≥1 inpatient and/or ≥2 outpatient claims with a diagnosis for schizophrenia in 2019. Summary statistics on AP use; HRU and cost; and quality measures were reported at the national, state, and county levels. Regional variation was measured using the coefficient of variation (CoV). We identified 314,888 beneficiaries with schizophrenia. About 91% used any AP; 20% used any long-acting injectable antipsychotic (LAI); and 14% used atypical LAIs. About 28% of beneficiaries had ≥1 hospitalization and 47% had ≥1 emergency room (ER) visits, the vast majority of which were related to mental health (MH). Total annual all-cause, MH, and schizophrenia-related costs were $23,662, $15,000 and $12,109, respectively. Among those with hospitalizations, 18.4% and 27.3% had readmission within 7 and 30 days and 56% and 67% had a physician visit and AP fill within 30 days post-discharge, respectively. Overall, 81% of beneficiaries were deemed adherent to their AP medications. Larger interstate variations were observed in LAI use than AP use (CoV: 0.21 vs 0.02). County-level variations were larger than state-level variations for all measures. In this first study examining a national sample of Medicare beneficiaries with schizophrenia, we found low utilization rates of LAIs and high levels of hospital admissions/readmissions and ER visits. State and county-level variations were also found in these measures.
DOI: 10.6084/m9.figshare.22332160.v3
title: Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States

description: No research to date has examined antipsychotic (AP) use, healthcare resource use (HRU), costs, and quality of care among those with schizophrenia in the Medicare program despite it serving as the primary payer for half of individuals with schizophrenia in the US. To provide national estimates and assess regional variation in AP treatment utilization, HRU, costs, and quality measures among Medicare beneficiaries with schizophrenia. Cross-sectional descriptive analysis of 100% Medicare claims data from 2019. The sample included all adult Medicare beneficiaries with continuous fee-for-service coverage and ≥1 inpatient and/or ≥2 outpatient claims with a diagnosis for schizophrenia in 2019. Summary statistics on AP use; HRU and cost; and quality measures were reported at the national, state, and county levels. Regional variation was measured using the coefficient of variation (CoV). We identified 314,888 beneficiaries with schizophrenia. About 91% used any AP; 20% used any long-acting injectable antipsychotic (LAI); and 14% used atypical LAIs. About 28% of beneficiaries had ≥1 hospitalization and 47% had ≥1 emergency room (ER) visits, the vast majority of which were related to mental health (MH). Total annual all-cause, MH, and schizophrenia-related costs were $23,662, $15,000 and $12,109, respectively. Among those with hospitalizations, 18.4% and 27.3% had readmission within 7 and 30 days and 56% and 67% had a physician visit and AP fill within 30 days post-discharge, respectively. Overall, 81% of beneficiaries were deemed adherent to their AP medications. Larger interstate variations were observed in LAI use than AP use (CoV: 0.21 vs 0.02). County-level variations were larger than state-level variations for all measures. In this first study examining a national sample of Medicare beneficiaries with schizophrenia, we found low utilization rates of LAIs and high levels of hospital admissions/readmissions and ER visits. State and county-level variations were also found in these measures.
DOI: 10.6084/m9.figshare.22233332
title: Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm

description: Real-world evidence is a valuable source of information in healthcare. This study describes the challenges and successes during algorithm development to identify cancer cohorts and multi-agent chemotherapy regimens from claims data to perform a comparative effectiveness analysis of granulocyte colony stimulating factor (G-CSF) use. Using the Biologics and Biosimilars Collective Intelligence Consortium’s Distributed Research Network, we iteratively developed and tested a de novo algorithm to accurately identify patients by cancer diagnosis, then extract chemotherapy and G-CSF administrations for a retrospective study of prophylactic G-CSF. After identifying patients with cancer and subsequent chemotherapy exposures, we observed only 12% of patients with cancer received chemotherapy, which is fewer than expected based on prior analyses. Therefore, we reversed the initial inclusion criteria to identify chemotherapy receipt, then prior cancer diagnosis, which increased the number of patients from 2,814 to 3,645, or 68% of patients receiving chemotherapy had diagnoses of interest. Additionally, we excluded patients with cancer diagnoses that differed from those of interest in the 183 days before the index date of G-CSF receipt, including early-stage cancers without G-CSF or chemotherapy exposure. By removing this criterion, we retained 77 patients who were previously excluded. Finally, we incorporated a 5-day window to identify all chemotherapy drugs administered (excluding oral prednisone and methotrexate, as these medications may be used for other non-malignant conditions) as patients may fill oral prescriptions days to weeks prior to infusion. This increased the number of patients with chemotherapy exposures of interest to 6,010. The final cohort of included patients, based on G-CSF exposure, increased from 420 from the initial algorithm to 886 using the final algorithm. Medications used for multiple indications, sensitivity and specificity of administrative codes, and relative timing of medication exposure must all be evaluated to identify patient cohorts receiving chemotherapy from claims data.
DOI: 10.6084/m9.figshare.22233332.v1
title: Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm

description: Real-world evidence is a valuable source of information in healthcare. This study describes the challenges and successes during algorithm development to identify cancer cohorts and multi-agent chemotherapy regimens from claims data to perform a comparative effectiveness analysis of granulocyte colony stimulating factor (G-CSF) use. Using the Biologics and Biosimilars Collective Intelligence Consortium’s Distributed Research Network, we iteratively developed and tested a de novo algorithm to accurately identify patients by cancer diagnosis, then extract chemotherapy and G-CSF administrations for a retrospective study of prophylactic G-CSF. After identifying patients with cancer and subsequent chemotherapy exposures, we observed only 12% of patients with cancer received chemotherapy, which is fewer than expected based on prior analyses. Therefore, we reversed the initial inclusion criteria to identify chemotherapy receipt, then prior cancer diagnosis, which increased the number of patients from 2,814 to 3,645, or 68% of patients receiving chemotherapy had diagnoses of interest. Additionally, we excluded patients with cancer diagnoses that differed from those of interest in the 183 days before the index date of G-CSF receipt, including early-stage cancers without G-CSF or chemotherapy exposure. By removing this criterion, we retained 77 patients who were previously excluded. Finally, we incorporated a 5-day window to identify all chemotherapy drugs administered (excluding oral prednisone and methotrexate, as these medications may be used for other non-malignant conditions) as patients may fill oral prescriptions days to weeks prior to infusion. This increased the number of patients with chemotherapy exposures of interest to 6,010. The final cohort of included patients, based on G-CSF exposure, increased from 420 from the initial algorithm to 886 using the final algorithm. Medications used for multiple indications, sensitivity and specificity of administrative codes, and relative timing of medication exposure must all be evaluated to identify patient cohorts receiving chemotherapy from claims data.